Litchlab, a global provider of next-generation nanomedicine delivery platforms, is accelerating the advancement of its Actively Targeted Liposome (ATL) technology to address the growing demand for precision drug delivery in oncology and other complex therapeutic areas. As the biopharmaceutical industry pivots toward targeted and combination therapies, Litchlab is harnessing cutting-edge ligand modification and formulation expertise to enable intelligent, tissue-specific delivery of small molecules, biologics, and nucleic acid therapeutics.
At the core of Litchlab’s ATL offering is an integrated R&D platform that brings together:
Ligand Screening & Conjugation: Litchlab supports a wide array of targeting ligands, including monoclonal antibodies, scFvs, peptides (e.g., RGD, cRGD), aptamers, and small molecules like folate. Site-specific conjugation strategies such as DSPE-PEG-maleimide and DSPE-PEG-biotin are employed to achieve >90% conjugation efficiency, while optimizing spatial orientation and steric stability.
Lipid Composition and Nanoarchitecture: Using FDA-compliant injectable-grade lipids (e.g., HSPC, DSPC, cholesterol), Litchlab engineers liposomes in the 80–120 nm range to maximize EPR-based tumor accumulation. Drug loading capabilities include hydrophobic (e.g., paclitaxel), hydrophilic (e.g., cisplatin), and nucleic acid payloads (siRNA, miRNA), with encapsulation efficiencies exceeding 90%.
Smart Release & In Vivo Evaluation: Controlled-release kinetics (6–48h half-life), enhanced cellular uptake via multivalent ligand clustering, and in vivo biodistribution analysis (e.g., NIR fluorescence imaging) ensure robust pharmacokinetic and pharmacodynamic profiles.
Litchlab’s ATL technology is currently being applied across multiple therapeutic categories:
Precision Oncology: Active targeting using anti-HER2, anti-EGFR, and RGD peptides has shown significant improvements in tumor accumulation and cytotoxicity. In xenograft models, ATL formulations outperformed standard liposomes by 2–5x in efficacy and reduced systemic toxicity by >40%.
Central Nervous System (CNS) Disorders: To overcome the blood-brain barrier (BBB), Litchlab is developing dual-targeting liposome systems integrating ligands such as transferrin receptor antibodies and RVG peptides, enabling delivery of siRNA and antibodies for glioblastoma and neurodegenerative conditions.
Rare Diseases: Litchlab supports clients developing liposome-based treatments for lysosomal storage diseases and gene editing approaches requiring precise tissue targeting.
Litchlab offers flexible, end-to-end CDMO services tailored to ATL programs:
Process Development: Dual-path manufacturing via microfluidics and film hydration-extrusion; batch-to-batch consistency (size, PDI, zeta) with<5% RSD.
CMC & Regulatory Support: ICH Q8/Q9/Q10-compliant documentation; support for IND/NDA submissions across FDA, NMPA, and EMA.
GMP Manufacturing: Scalable GMP production from 10 L to 100 L batches, with validated analytical methods and QbD frameworks.
Nonclinical Studies: In vivo safety, biodistribution, immunogenicity, PK/PD profiling, and biodegradation pathway support.
With over 12 active client projects—including three IND-stage programs—Litchlab’s ATL technology is rapidly becoming a preferred platform for innovators aiming to bring precision therapeutics to market faster and safer. By combining scientific rigor with scalable manufacturing and regulatory readiness, Litchlab is enabling breakthroughs in targeted drug delivery.
